Insider Selling: Alnylam Pharmaceuticals (NASDAQ:ALNY) EVP Sells 1,455 Shares of Stock

Key Points

• Pushkal Garg, EVP of Alnylam Pharmaceuticals, sold 1,455 shares of the company at an average price of $458.41, leading to a total transaction of approximately $666,986.55.
• Alnylam Pharmaceuticals reported $0.32 earnings per share for the last quarter, exceeding the consensus estimate and showcasing a 17.3% increase in revenue year-over-year.
• Several analysts upgraded Alnylam's stock ratings, with a consensus average price target of $405.33 and notable upgrades from firms like Oppenheimer and JPMorgan Chase & Co.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Get Free Report) EVP Pushkal Garg sold 1,455 shares of the business's stock in a transaction that occurred on Tuesday, August 19th. The stock was sold at an average price of $458.41, for a total value of $666,986.55. Following the completion of the sale, the executive vice president directly owned 20,221 shares in the company, valued at approximately $9,269,508.61. This represents a 6.71% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Pushkal Garg also recently made the following trade(s):

• On Monday, August 18th, Pushkal Garg sold 1,396 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $453.27, for a total value of $632,764.92.

Alnylam Pharmaceuticals Stock Down 2.8%

Shares of ALNY traded down $13.17 during mid-day trading on Friday, reaching $454.38. The company had a trading volume of 1,075,489 shares, compared to its average volume of 1,386,802. The company has a debt-to-equity ratio of 4.10, a quick ratio of 2.75 and a current ratio of 2.80. The firm has a 50-day moving average price of $360.65 and a 200 day moving average price of $296.84. Alnylam Pharmaceuticals, Inc. has a 52 week low of $205.87 and a 52 week high of $469.81. The company has a market capitalization of $59.56 billion, a price-to-earnings ratio of -183.96 and a beta of 0.25.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 EPS for the quarter, topping analysts' consensus estimates of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.The firm had revenue of $773,689 billion for the quarter, compared to analysts' expectations of $633.54 million. During the same period in the previous year, the firm posted ($0.13) EPS. The business's revenue for the quarter was up 17.3% compared to the same quarter last year. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. On average, sell-side analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Analyst Ratings Changes

A number of brokerages have recently commented on ALNY. Truist Financial began coverage on Alnylam Pharmaceuticals in a research report on Monday, July 21st. They issued a "buy" rating and a $385.00 price target on the stock. JPMorgan Chase & Co. boosted their price objective on shares of Alnylam Pharmaceuticals from $348.00 to $475.00 and gave the stock an "overweight" rating in a report on Wednesday, August 6th. Needham & Company LLC boosted their price objective on shares of Alnylam Pharmaceuticals from $377.00 to $478.00 and gave the stock a "buy" rating in a report on Thursday, July 31st. BMO Capital Markets boosted their price objective on shares of Alnylam Pharmaceuticals from $300.00 to $360.00 and gave the stock an "outperform" rating in a report on Tuesday, June 24th. Finally, Raymond James Financial began coverage on shares of Alnylam Pharmaceuticals in a report on Wednesday, July 30th. They issued an "outperform" rating and a $370.00 price objective for the company. Twenty-two analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $405.33.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in ALNY. Brighton Jones LLC purchased a new stake in Alnylam Pharmaceuticals during the 4th quarter valued at $243,000. Townsquare Capital LLC purchased a new stake in Alnylam Pharmaceuticals during the 4th quarter valued at $227,000. Mariner LLC raised its stake in Alnylam Pharmaceuticals by 16.6% during the 4th quarter. Mariner LLC now owns 13,666 shares of the biopharmaceutical company's stock valued at $3,216,000 after buying an additional 1,947 shares during the last quarter. NewEdge Advisors LLC raised its stake in Alnylam Pharmaceuticals by 97,200.0% during the 4th quarter. NewEdge Advisors LLC now owns 973 shares of the biopharmaceutical company's stock valued at $229,000 after buying an additional 972 shares during the last quarter. Finally, CANADA LIFE ASSURANCE Co raised its stake in Alnylam Pharmaceuticals by 11.9% during the 4th quarter. CANADA LIFE ASSURANCE Co now owns 76,919 shares of the biopharmaceutical company's stock valued at $18,087,000 after buying an additional 8,206 shares during the last quarter. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.